Modeling new therapies for infantile spasms

Lenka Chudomelova, Morris H. Scantlebury, Emmanuel Raffo, Antonietta Coppola, David Betancourth, Aristea S. Galanopoulou

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Infantile spasms are the classical seizure type of West syndrome. Infantile spasms often herald a dismal prognosis, due to the high probability to evolve into intractable forms of epilepsies with significant cognitive deficits, especially if not adequately treated. The current therapies - high doses of adrenocorticotropic hormone, steroids, or the γ-aminobutyric acid (GABA) transaminase inhibitor vigabatrin - are often toxic and may not always be effective. The need to identify new therapies for spasms has led to the generation of a number of rodent models of infantile spasms. These include acute and chronic models of infantile spasms, with cryptogenic or symptomatic origin, many of which are based on specific etiologies. In this review, we summarize the clinical experience with treating infantile spasms and the main features of the new animal models of infantile spasms and discuss their utility in the preclinical development of new therapies for infantile spasms.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalEpilepsia
Volume51
Issue numberSUPPL. 3
DOIs
StatePublished - Jul 2010

Fingerprint

Infantile Spasms
Therapeutics
4-Aminobutyrate Transaminase
Vigabatrin
Aminobutyrates
Poisons
Spasm
Adrenocorticotropic Hormone
Rodentia
Seizures
Animal Models
Steroids

Keywords

  • Adrenocorticotropic hormone
  • Infantile spasms
  • Models
  • mTOR
  • Rapamycin
  • Vigabatrin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Chudomelova, L., Scantlebury, M. H., Raffo, E., Coppola, A., Betancourth, D., & Galanopoulou, A. S. (2010). Modeling new therapies for infantile spasms. Epilepsia, 51(SUPPL. 3), 27-33. https://doi.org/10.1111/j.1528-1167.2010.02605.x

Modeling new therapies for infantile spasms. / Chudomelova, Lenka; Scantlebury, Morris H.; Raffo, Emmanuel; Coppola, Antonietta; Betancourth, David; Galanopoulou, Aristea S.

In: Epilepsia, Vol. 51, No. SUPPL. 3, 07.2010, p. 27-33.

Research output: Contribution to journalArticle

Chudomelova, L, Scantlebury, MH, Raffo, E, Coppola, A, Betancourth, D & Galanopoulou, AS 2010, 'Modeling new therapies for infantile spasms', Epilepsia, vol. 51, no. SUPPL. 3, pp. 27-33. https://doi.org/10.1111/j.1528-1167.2010.02605.x
Chudomelova L, Scantlebury MH, Raffo E, Coppola A, Betancourth D, Galanopoulou AS. Modeling new therapies for infantile spasms. Epilepsia. 2010 Jul;51(SUPPL. 3):27-33. https://doi.org/10.1111/j.1528-1167.2010.02605.x
Chudomelova, Lenka ; Scantlebury, Morris H. ; Raffo, Emmanuel ; Coppola, Antonietta ; Betancourth, David ; Galanopoulou, Aristea S. / Modeling new therapies for infantile spasms. In: Epilepsia. 2010 ; Vol. 51, No. SUPPL. 3. pp. 27-33.
@article{ecc5270ab8df425daa1bb12cd618f8fd,
title = "Modeling new therapies for infantile spasms",
abstract = "Infantile spasms are the classical seizure type of West syndrome. Infantile spasms often herald a dismal prognosis, due to the high probability to evolve into intractable forms of epilepsies with significant cognitive deficits, especially if not adequately treated. The current therapies - high doses of adrenocorticotropic hormone, steroids, or the γ-aminobutyric acid (GABA) transaminase inhibitor vigabatrin - are often toxic and may not always be effective. The need to identify new therapies for spasms has led to the generation of a number of rodent models of infantile spasms. These include acute and chronic models of infantile spasms, with cryptogenic or symptomatic origin, many of which are based on specific etiologies. In this review, we summarize the clinical experience with treating infantile spasms and the main features of the new animal models of infantile spasms and discuss their utility in the preclinical development of new therapies for infantile spasms.",
keywords = "Adrenocorticotropic hormone, Infantile spasms, Models, mTOR, Rapamycin, Vigabatrin",
author = "Lenka Chudomelova and Scantlebury, {Morris H.} and Emmanuel Raffo and Antonietta Coppola and David Betancourth and Galanopoulou, {Aristea S.}",
year = "2010",
month = "7",
doi = "10.1111/j.1528-1167.2010.02605.x",
language = "English (US)",
volume = "51",
pages = "27--33",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Modeling new therapies for infantile spasms

AU - Chudomelova, Lenka

AU - Scantlebury, Morris H.

AU - Raffo, Emmanuel

AU - Coppola, Antonietta

AU - Betancourth, David

AU - Galanopoulou, Aristea S.

PY - 2010/7

Y1 - 2010/7

N2 - Infantile spasms are the classical seizure type of West syndrome. Infantile spasms often herald a dismal prognosis, due to the high probability to evolve into intractable forms of epilepsies with significant cognitive deficits, especially if not adequately treated. The current therapies - high doses of adrenocorticotropic hormone, steroids, or the γ-aminobutyric acid (GABA) transaminase inhibitor vigabatrin - are often toxic and may not always be effective. The need to identify new therapies for spasms has led to the generation of a number of rodent models of infantile spasms. These include acute and chronic models of infantile spasms, with cryptogenic or symptomatic origin, many of which are based on specific etiologies. In this review, we summarize the clinical experience with treating infantile spasms and the main features of the new animal models of infantile spasms and discuss their utility in the preclinical development of new therapies for infantile spasms.

AB - Infantile spasms are the classical seizure type of West syndrome. Infantile spasms often herald a dismal prognosis, due to the high probability to evolve into intractable forms of epilepsies with significant cognitive deficits, especially if not adequately treated. The current therapies - high doses of adrenocorticotropic hormone, steroids, or the γ-aminobutyric acid (GABA) transaminase inhibitor vigabatrin - are often toxic and may not always be effective. The need to identify new therapies for spasms has led to the generation of a number of rodent models of infantile spasms. These include acute and chronic models of infantile spasms, with cryptogenic or symptomatic origin, many of which are based on specific etiologies. In this review, we summarize the clinical experience with treating infantile spasms and the main features of the new animal models of infantile spasms and discuss their utility in the preclinical development of new therapies for infantile spasms.

KW - Adrenocorticotropic hormone

KW - Infantile spasms

KW - Models

KW - mTOR

KW - Rapamycin

KW - Vigabatrin

UR - http://www.scopus.com/inward/record.url?scp=77954466566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954466566&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2010.02605.x

DO - 10.1111/j.1528-1167.2010.02605.x

M3 - Article

C2 - 20618396

AN - SCOPUS:77954466566

VL - 51

SP - 27

EP - 33

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 3

ER -